IXHL vs. AUPH, PLRX, LBPH, PAHC, ANAB, MLYS, NUVB, SAGE, DNTH, and RNAC
Should you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include Aurinia Pharmaceuticals (AUPH), Pliant Therapeutics (PLRX), Longboard Pharmaceuticals (LBPH), Phibro Animal Health (PAHC), AnaptysBio (ANAB), Mineralys Therapeutics (MLYS), Nuvation Bio (NUVB), Sage Therapeutics (SAGE), Dianthus Therapeutics (DNTH), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical preparations" industry.
Incannex Healthcare (NASDAQ:IXHL) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings.
Aurinia Pharmaceuticals received 567 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
Incannex Healthcare has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -32.69%. Incannex Healthcare's return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.
Incannex Healthcare has higher earnings, but lower revenue than Aurinia Pharmaceuticals.
Incannex Healthcare has a beta of 8.36, suggesting that its stock price is 736% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.
Aurinia Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 88.68%. Given Aurinia Pharmaceuticals' higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Incannex Healthcare.
0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 14.6% of Incannex Healthcare shares are owned by company insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.90 beat Aurinia Pharmaceuticals' score of 1.10 indicating that Incannex Healthcare is being referred to more favorably in the media.
Summary
Incannex Healthcare beats Aurinia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Incannex Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Incannex Healthcare Competitors List
Related Companies and Tools
